Analysts Offer Predictions for AQST FY2026 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56) for the year. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analyst estimates of $13.11 million.

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective for the company. Raymond James set a $7.00 target price on Aquestive Therapeutics in a report on Friday. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday. Finally, Alliance Global Partners restated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $10.57.

Remove Ads

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $2.54 on Tuesday. The company's fifty day moving average is $3.07 and its two-hundred day moving average is $4.09. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The stock has a market capitalization of $251.13 million, a price-to-earnings ratio of -5.64 and a beta of 2.76.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after acquiring an additional 621,614 shares in the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company's stock valued at $7,454,000 after purchasing an additional 512,682 shares during the period. Stifel Financial Corp increased its position in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock worth $1,419,000 after acquiring an additional 302,617 shares in the last quarter. Harvey Capital Management Inc. raised its holdings in shares of Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after acquiring an additional 249,790 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $995,000. Institutional investors and hedge funds own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.